Regeneron's EYLEA HD posts Phase 3b safety results; dupilumab keloid study completesSep 18Weekly roundup, 2 itemsafliberceptdupilumab
Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trialsAug 28Weekly roundup, 6 itemsberobenatidePF-08154225
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
Sign inSign in